Pulmonary Hypertension

Re: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study - The BMJ Re: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study - The BMJ Posted: 26 Mar 2020 12:00 AM PDT Dear Editor This is an interesting article from a Paediatric Surgeon's perspective. We would like to highlight the possibility of histopathology similarity between the critically ill SARS-Cov-2 patients to moribund infants with a congenital diaphragmatic hernia (CDH). Hopefully, this may lead to a possible lead upon clinical management of the acutely ill SARS-CoV-2 patients. A) CLINICAL COURSE SIMILARITY: The novel coronavirus disease 2019 (COVID-19) can induce acute respiratory distress syndrome (ARDS), which can progress to refractory pulmonary failure. The mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivo...

Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension - GlobeNewswire Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension - GlobeNewswire Posted: 30 Apr 2020 04:33 AM PDT RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that it has released final safety and tolerability results from the two-month endpoint of the pivotal phase 3 INSPIRE trial that evaluated LIQ861 in patients with pulmonary arterial hypertension (PAH). Details from this late-breaking abstract were provided as an ePresentation on ISHLTv, an online platform designed as an alternative to the face-to-face scienti...

United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension - PRNewswire United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension - PRNewswire Posted: 23 Apr 2020 03:00 AM PDT SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 23, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR ) today detailed recent publications on Orenitram ® (treprostinil) Extended-Release Tablets, which provide additional evidence of the beneficial treatment effect in patients with pulmonary arterial hypertension (PAH). Continue Reading (PRNewsfoto/United Therapeutics Corporation) (PRNewsfoto/United Therapeutics Corporation) Ore...

RA Conduit Phase Emptying May Predict Adverse Event Risk in Pediatric PAH - Pulmonology Advisor RA Conduit Phase Emptying May Predict Adverse Event Risk in Pediatric PAH - Pulmonology Advisor Posted: 29 Apr 2020 08:30 AM PDT Right atrial (RA) conduit phase emptying may predict the risk for adverse clinical events in pediatric patients with pulmonary arterial hypertension (PAH), according to study results published in the Journal of the American Society of Echocardiography . Researchers conducted a single center prospective cohort analysis of 41 patients (median age, 11.9 years) with idiopathic or heritable PAH to examine the usefulness of RA fractional emptying indices in the prognosis of pediatric PAH. Patients were age- and sex-matched with control individuals in a 1:1 ratio and were all evaluated using echo- and electrocardiography. An adverse clinical event was defined as initiation of parenteral prostanoid therapy, PAH-related hospita...

Experts Issue Guidance on Use of Oral PPAs, Like Uptravi, in... - Pulmonary Hypertension News Experts Issue Guidance on Use of Oral PPAs, Like Uptravi, in... - Pulmonary Hypertension News Posted: 03 Apr 2020 12:00 AM PDT A consensus on the use of oral prostacyclin pathway agents (PPAs), like Uptravi (selexipag) , as an add-on to standard therapies for certain types of pulmonary arterial hypertension (PAH) was announced by a 19-physician expert panel. PPAs can be an adjunct therapy to standard vasodilator compounds —  endothelin receptor antagonists (ERAs) and phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) — in treating  functional class (FC) II or III  PAH patients. But differing recommendations as to the best timing and circumstances for their use are a source of confusion. Treatment guidelines defined by the Prostacyclin International Expert Panel were described in the study, " Results...